Described herein in one embodiment is a computer-implemented method comprising accessing information representing a detection component of a diagnostic test and determining, based at least in part on the information representing the detection component of the diagnostic test, results of the diagnostic test. Described herein in one embodiment is a method of performing a diagnostic test on a subject. In one embodiment, the method comprises obtaining a sample from the subject, processing the sample, analyzing the sample with a detection component of the diagnostic test, and performing a computer-implemented method comprising accessing information representing the detection component of a diagnostic test, and determining, based at least in part on the information representing the detection component of the diagnostic test, results of the diagnostic test.

Described herein in one embodiment is software, which may be downloaded to a device, to guide a user through administration of a test. Test results may be uploaded, manually or automatically, to a device or communicated remotely through a network. In an embodiment, the test is a rapid test. In an embodiment, the rapid test detects presence of COVID-19. In an embodiment, the rapid test detects COVID-19 or influenza. In an embodiment, the rapid test detects influenza A or influenza B. In an embodiment, the rapid test detects a target nucleic acid. In an embodiment, the target nucleic acid represents one of a viral, bacterial, fungal, parasitic or protozoan pathogen. Each of the rapid tests may be self administrable.

Described herein in one embodiment is software, which may be downloaded to a device, to guide a user through administration of a test. Test results may be uploaded, manually or automatically, to a device or communicated remotely through a network. In an embodiment, the test is a rapid test. In an embodiment, the rapid test detects presence of COVID-19. In an embodiment, the rapid test detects COVID-19 or influenza. In an embodiment, the rapid test detects influenza A or influenza B. In an embodiment, the rapid test detects a target nucleic acid. In an embodiment, the target nucleic acid represents one of a viral, bacterial, fungal, parasitic or protozoan pathogen. Each of the rapid tests may be self administrable.

This invention relates to a method of characterizing the modified base status of a transcriptome, which involves contacting a transcriptome comprising one or more modified bases with an antibody specific to the modified bases under conditions effective to bind the antibody to the modified bases; isolating, from the transcriptome, a pool of RNA transcripts to which the antibody binds; and identifying isolated RNA transcripts that are present in a higher abundance in the isolated pool relative to the transcriptome, where each of the isolated RNA transcripts that are present in a higher abundance in the isolated pool together characterize the modified base status of the transcriptome. Also disclosed are a method of diagnosis or prognosis of a disease, a method of determining the effect of a treatment on modified base levels in RNA, and a kit for characterizing the modified base status of a transcriptome.

This invention relates to a method of characterizing the modified base status of a transcriptome, which involves contacting a transcriptome comprising one or more modified bases with an antibody specific to the modified bases under conditions effective to bind the antibody to the modified bases; isolating, from the transcriptome, a pool of RNA transcripts to which the antibody binds; and identifying isolated RNA transcripts that are present in a higher abundance in the isolated pool relative to the transcriptome, where each of the isolated RNA transcripts that are present in a higher abundance in the isolated pool together characterize the modified base status of the transcriptome. Also disclosed are a method of diagnosis or prognosis of a disease, a method of determining the effect of a treatment on modified base levels in RNA, and a kit for characterizing the modified base status of a transcriptome.

Method for detecting the presence of nucleases in a sample, characterized in that it comprises the steps of: incubating the sample to be tested for the presence of nucleases with at least one oligonucleotide linker constituting the substrate for the nuclease to be detected, for a sufficient time to cause degradation of said oligonucleotide linker by the nuclease possibly present in the sample, adding to the sample, upon incubation, colloidal gold nanoparticles comprising gold nanoparticles functionalized with a first probe oligonucleotide and gold nanoparticles functionalized with a respective second probe oligonucleotide, said first and second probe oligonucleotides being complementary to a respective portion of the nucleotide sequence of the oligonucleotide linker, andexamining the possible colour change of the sample as a result of the addition of said nanoparticles, a colour change of the sample to the colour assumed by the colloidal gold particles when aggregated at a distance less than their size being indicative of the absence of the tested nuclease from the sample.

The invention relates to the identification of secretory antibody-bound bacteria in the microbiota in a subject that influence the development and progression of inflammatory diseases and disorders. Thus, the invention relates to compositions and methods for detecting and identifying the constituents of a subject's microbiota, methods of modifying the constituents of the microbiota, and methods for treating inflammatory diseases and disorders in a subject in need thereof.

The invention relates to the identification of secretory antibody-bound bacteria in the microbiota in a subject that influence the development and progression of inflammatory diseases and disorders. Thus, the invention relates to compositions and methods for detecting and identifying the constituents of a subject's microbiota, methods of modifying the constituents of the microbiota, and methods for treating inflammatory diseases and disorders in a subject in need thereof.

The invention relates to the identification of secretory antibody-bound bacteria in the microbiota in a subject that influence the development and progression of inflammatory diseases and disorders. Thus, the invention relates to compositions and methods for detecting and identifying the constituents of a subject's microbiota, methods of modifying the constituents of the microbiota, and methods for treating inflammatory diseases and disorders in a subject in need thereof.

The invention relates to the identification of secretory antibody-bound bacteria in the microbiota in a subject that influence the development and progression of inflammatory diseases and disorders. Thus, the invention relates to compositions and methods for detecting and identifying the constituents of a subject's microbiota, methods of modifying the constituents of the microbiota, and methods for treating inflammatory diseases and disorders in a subject in need thereof.